Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132

Annals of Surgical Oncology

Volumn 19, Issue 4, 2012, Pages 1074-1080

  Wang, Dian ^a   Zhang, Qiang ^b   Blanke, Charles D ^c   Demetri, George D ^d   Heinrich, Michael C ^e   Watson, James C ^f   Hoffman, John P ^f   Okuno, Scott ^g   Kane, John M ^h   Von Mehren, Margaret ^f   Eisenberg, Burton L ⁱ  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b RADIATION THERAPY ONCOLOGY GROUP   (United States)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d HARVARD MEDICAL SCHOOL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g MAYO CLINIC   (United States)

^h ROSWELL PARK CANCER INSTITUTE   (United States)

ⁱ DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER SPECIFIC SURVIVAL; CARDIOTOXICITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EYE DISEASE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TOXICITY; HEART ARRHYTHMIA; HUMAN; ILEUS; LIVER TOXICITY; LUNG TOXICITY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NEUROTOXICITY; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL DISORDER;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861759106     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2190-5     Document Type: Article

References (31)

1. Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Network. 2010;8:S1-41.
2. Casali PG, Jost L, Reichardt P, et al. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):64-7.
3. Corless CL, Heinrich MC. Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol. 2008;3:557-86. (Pubitemid 351488293)
4. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459-65. (Pubitemid 34747864)
5. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708-10. (Pubitemid 36159485)
6. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80. (Pubitemid 34879334)
7. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9669):1097- 104.
8. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626-32. (Pubitemid 351264358)
9. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26:620-5. (Pubitemid 351264357)
10. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127-34. (Pubitemid 39296599)
11. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751-7. (Pubitemid 41132637)
12. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006;42:1093-103. (Pubitemid 44275331)
13. Le Cesne A, Van Glabbeke M, Verweij J, et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. J Clin Oncol. 2009;27:3969-74.
14. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42-7.
15. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol. 2009;16:910-9.
16. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
18. Therasse P, Arbuck S, Eisenhauer E, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16. (Pubitemid 30099779)
19. Blackstein ME, Blay JY, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Can J Gastroenterol. 2006;20:157-63.
20. Le Cesne A, Ray-Coquard I, Bui BN, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11:942-9.
21. Hassan I, You YN, Shyyan R, et al. Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Ann Surg Oncol. 2008;15:52-9.
22. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002;20:3898-905.
23. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466-78. (Pubitemid 44520713)
24. Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411-9.
25. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 2008;112:608-15. (Pubitemid 351186201)
26. Joensuu H. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of randomized trial (SSGXVIII/AIO). J Clin Oncol. 2011;(18 Suppl):29.
27. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14-24. (Pubitemid 44954266)
28. Bonvalot S, Eldweny H, Péchoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13:1596-603. (Pubitemid 44951467)
29. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol. 2006;93:304-11.
30. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006;24:2325-31. (Pubitemid 46630664)
31. Blesius A, Cassier PA, Bertucci F, et al. Neoadjuvant IM in patients with locally advanced GIST in the prospective BFR14 trial. BMC Cancer. 2011;11:72.